Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference.

Details of the event is as follows:

SVB Securities Global Biopharma Conference, February 14-15, 2023 (virtual)

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our lead candidate is epetraborole, which we are studying in a pivotal Phase 2/3 trial as a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.

These press releases may also interest you

at 08:11
Despite the glowing testimonials from consumers in advertisements promoting hair supplements to combat hair loss and thinning, hair restoration experts warn that consuming supplements without getting to the root of what is causing hair thinning may...

at 08:06
Human Appeal, a leading global humanitarian charity, revealed that a delegation of UN officials visited one of its key projects in northwest Syria offering shelter and relief to thousands of internally displaced families....

at 08:05
Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase...

at 08:05
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer.  Earlier this year, scientists from Columbia University in New York demonstrated that the growth rate of pancreatic cancer,...

at 08:02
Kauhale Health ("Kauhale") has acquired assisted living and memory care community The Parker (Greenville, SC). This marks Kauhale's second acquisition and a further step in the execution of a deliberate senior living investment and management...

at 08:00
BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has closed a non-brokered private...

News published on and distributed by: